{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-115334","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.442110+00:00","generated_at":"2026-05-30T03:13:19.651239+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%","bullets":["Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.","TAVALISSE net sales $26.3M (+8% YoY); REZLIDHIA $5.5M (+107% YoY); GAVRETO $7.1M (first full quarter).","Received $10M upfront from Kissei license for REZLIDHIA in Japan, Korea, Taiwan; up to $152.5M milestones.","R289 Phase 1b in LR-MDS: RBC-TI/hematologic improvement in 36% at doses ≥500 mg QD; median duration 29 weeks.","Cash and investments $61.1M at Sep 30, up from $49.1M at Jun 30 and $56.9M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-115334","json":"https://secwatch.observer/filing/0001104659-24-115334.json","markdown":"https://secwatch.observer/filing/0001104659-24-115334.md","text":"https://secwatch.observer/filing/0001104659-24-115334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/0001104659-24-115334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/tm2427717d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:13:19.651239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}